
FDA Approves Wilserdly Combo for ESR1-Mutated Breast Cancer
Key Takeaways
- Label restricts use to ER-positive/HER2-negative, ESR1-mutated advanced disease with progression on prior endocrine therapy; mutation detection must use an FDA-authorized assay, including FoundationOne Liquid CDx.
- Phase 3 evERA (n=373; ESR1-mutated n=207) demonstrated median PFS 10.0 vs 5.5 months with giredestrant vs control endocrine therapy, both with everolimus (62% risk reduction).
The FDA approved Wilserdly with everolimus for some ER-positive, HER2-negative, ESR1-mutated advanced breast cancers that grew after prior hormone therapy.
The Food and Drug Administration (FDA) approved Wilserdly (giredestrant) in combination with everolimus for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated breast cancer that is locally advanced or has spread (metastatic).
The approval, announced Nov. 16, covers patients whose cancer came back during or after hormone (endocrine) therapy given after surgery, or whose cancer grew on at least one hormone therapy-based treatment for metastatic disease. The ESR1 mutation must be found with an FDA-authorized test. The agency approved FoundationOne Liquid CDx, a blood test, as the companion test to identify patients whose breast cancer has an ESR1 mutation.
Wilserdly is a pill that blocks the estrogen receptor, which some breast cancers rely on to grow. ESR1 mutations often develop after a person has been on hormone therapy for advanced breast cancer and can help the cancer keep growing despite treatment. Everolimus, also known by the brand name Afinitor, is a targeted therapy already used in advanced hormone receptor-positive breast cancer. The FDA approved the combination four weeks ahead of its goal date, after the agency
What the evERA Trial Showed
The approval is based on the phase 3 evERA Breast Cancer trial, which enrolled 373 adults with ER-positive, HER2-negative advanced breast cancer, including 207 whose tumors had an ESR1 mutation. Patients were randomly assigned to take Wilserdly or their doctor’s choice of hormone therapy (exemestane, fulvestrant or tamoxifen). Everyone in the trial also took everolimus.
Among patients with ESR1-mutated cancer, those who took Wilserdly with everolimus went a median of 10 months before their cancer grew or they died (progression-free survival), compared with 5.5 months for those who took standard hormone therapy with everolimus. That translated to a 62% lower risk of cancer progression or death.
Tumors shrank in 27% of patients in the Wilserdly group, compared with 14% of patients in the comparison group. It is not yet known whether the combination helps patients live longer, because overall survival data were not mature at the time of the analysis. CURE previously reported that the combination
Side Effects to Know About
The most common side effects, seen in at least 20% of patients, were mouth sores (stomatitis), rash, fatigue, diarrhea, muscle and bone pain, inflammation of the lungs (pneumonitis) and nausea. Common lab changes included low blood counts, low calcium, potassium and sodium levels, and increases in liver enzymes and creatinine, a measure of kidney function.
The prescribing information also warns about a slow heart rate (bradycardia) and possible harm to a developing baby. Patients should tell their care team about any lightheadedness, dizziness or fainting, and should talk with their doctor about birth control during treatment.
How Wilserdly Is Taken
The recommended dose of Wilserdly is 30 mg by mouth once a day, with or without food, until the cancer grows or side effects become too difficult to manage. Everolimus is taken according to its own prescribing information. In the trial, premenopausal women and men also received medication to lower hormone levels, unless men had had both testicles removed.
Questions to Ask Your Care Team
- Has my cancer been tested for an ESR1 mutation, and should I have a blood test to check?
- Would Wilserdly with everolimus be an option if my cancer grows on my current hormone therapy?
- How will we watch for and manage side effects such as mouth sores, lung inflammation or a slow heart rate?
- How does this combination compare with other options for my situation?
Reference
- “FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.” U.S. Food and Drug Administration. Nov. 16, 2026.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
For more news on cancer updates, research and education,
Related to this article








